| Futile reperfusion (3-month mRS 3–6 with TICI grade 2b–3) n = 226 | No-futile reperfusion (3-month mRS 0–2 with TICI grade 2b–3) n = 214 | P-value |
---|---|---|---|
Age, mean ± SD | 70.3 ± 12.1 | 64.0 ± 11.8 | 0.08d |
Male, % | 120 (53.1) | 135 (63.1) | 0.04a |
TOAST | Â | Â | 0.96a |
 LAA | 51 (22.6) | 50 (23.4) |  |
 CE | 131 (58.0) | 121 (56.5) |  |
 others | 44 (19.5) | 43 (20.1) |  |
Hypertension, % | 151 (66.8) | 122 (57.0) | 0.04a |
Diabetes mellitus, % | 58 (25.7) | 42 (19.6) | 0.14a |
Hyperlipidemia, % | 46 (20.4) | 47 (22.0) | 0.73a |
Current Smoking, % | 37 (16.4) | 62 (29.0) | 0.002a |
Atrial fibrillation, % | 120 (53.1) | 108 (50.5) | 0.63a |
NIHSS, IQR | 16 (12–19) | 12 (8–17) | < 0.001c |
 NIHSS ≤5 | 9 (4.0) | 34 (15.9) | < 0.001a |
 NIHSS 6~10 | 28 (12.4) | 53 (24.8) |  |
 NIHSS 11~20 | 152 (67.3) | 106 (49.5) |  |
 NIHSS > 20 | 37 (16.4) | 21 (9.8) |  |
Pre-stroke antithrombotics, % | 83 (36.7) | 93 (43.5) | 0.17a |
Pre-stroke statin, % | 46 (20.4) | 46 (21.5) | 0.82a |
SBP, mean ± SD | 143.7 ± 27.3 | 138.4 ± 27.0 | 0.92d |
Creatinine, mg/dL, mean ± SD | 0.97 ± 0.48 | 0.92 ± 0.28 | 0.02d |
Total cholesterol, mg/dL, mean ± SD | 165.4 ± 39.7 | 166.1 ± 40.6 | 0.84d |
Initial random glucose, mg/dL, mean ± SD | 139.5 ± 49.2 | 130.0 ± 41.5 | 0.20d |
Preceding IVT, % | 154 (68.1) | 154 (72.0) | 0.41a |
Onset to EVT start time, min, mean ± SD | 257.4 ± 110.9 | 245.3 ± 124.0 | 0.18d |
Location of occlusion, % | Â | Â | 0.66a |
 MCA | 119 (52.7) | 122 (57.0) |  |
 ICA | 56 (24.8) | 49 (22.9) |  |
 MCA + ICA | 51 (22.6) | 43 (20.1) |  |
Location of lesions, % | |||
 Right hemisphere | 110 (48.7) | 110 (51.4) | 0.64a |
 Left hemisphere | 111 (49.1) | 97 (45.3) |  |
 Both hemisphere | 5 (2.2) | 7 (3.3) |  |
Symptomatic HT | 20 (8.8) | 6 (2.8) | < 0.001b |
Neurologic progression* | 40 (17.7) | 22 (10.3) | < 0.001b |